Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Looking forward to EHA 2021

Steven Treon • 1 Jun 2021
EHA 2021
General Antibodies Rituximab Zanubrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, highlights key abstracts being presented at EHA 2021, including an abstract comparing zanabrutinib to matched controls. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Steven Treon, MD, PhD, has received research funding and consulting fees from Abbvie/Pharmacyclics, Janssen, Beigene, Eli Lilly and X4.

More from Steven Treon

How do tumor subclones and T-cell dynamics influence ibrutinib responses in Waldenström’s?
2:23
How do tumor subclones and T-cell dynamics influence ibrutinib responses in Waldenström’s?
Steven Treon • 14 May 2026
How do the clinicopathological features of IgM-MM and WM differ?
1:12
How do the clinicopathological features of IgM-MM and WM differ?
Steven Treon • 14 May 2026
The current status of bispecifics and CAR-T in Waldenström’s macroglobulinemia
2:01
The current status of bispecifics and CAR-T in Waldenström’s macroglobulinemia
Steven Treon • 14 May 2026
The role of BTK inhibitors in the current treatment landscape for WM
2:32
The role of BTK inhibitors in the current treatment landscape for WM
Steven Treon • 14 May 2026

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI in clinical decision-making
2:25
Addressing the risk of over-reliance on AI in clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026
The content of VJHemOnc is intended for healthcare professionals